Lusutrombopag Disease Interactions
There are 2 disease interactions with lusutrombopag.
Lusutrombopag (applies to lusutrombopag) severe renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Pharmacokinetics information in patients with severe renal impairment (CrCl less than 30 mL/min) is limited. Caution is advised if using in this patient population.
References
- (2018) "Product Information. Mulpleta (lusutrombopag)." Shionogi USA Inc
TPO receptor agonists (applies to lusutrombopag) thrombotic / thromboembolic complications
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder, Protein C Deficiency
Thromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag. Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).
References
- (2008) "Product Information. Promacta (eltrombopag)." GlaxoSmithKline
- (2018) "Product Information. Doptelet (avatrombopag)." Dova Pharmaceuticals
- (2018) "Product Information. Mulpleta (lusutrombopag)." Shionogi USA Inc
Lusutrombopag drug interactions
There are 148 drug interactions with lusutrombopag.
More about lusutrombopag
- lusutrombopag consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: platelet-stimulating agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.